PUBLISHER: The Business Research Company | PRODUCT CODE: 1672491
PUBLISHER: The Business Research Company | PRODUCT CODE: 1672491
A microbiome refers to a community of microbes inhabiting a specific habitat, comprising fungi, bacteria, and viruses. It encompasses all the genetic material of bacteria, fungi, protozoa, and viruses that reside on and within the human body. The bacteria within the microbiome play crucial roles in digestion, immune system regulation, defense against disease-causing bacteria, and the production of essential vitamins such as Vitamin K, necessary for blood clotting, and B vitamins such as B12, thiamine, and riboflavin.
The primary types of microbiomes include bacteria, archaea, viruses, and other microorganisms. Bacteria, single-celled microorganisms belonging to the domain Bacteria, are diverse and abundant life forms found in various environments. Products associated with microbiomes include therapeutics and diagnostics, and technologies such as genomics, proteomics, and metabolomics are employed in conditions such as inflammatory bowel disease, gastrointestinal disorders, metabolic disorders, cancers, and other diseases.
The microbiome market research report is one of a series of new reports from The Business Research Company that provides microbiome market statistics, including microbiome industry global market size, regional shares, competitors with a microbiome market share, detailed microbiome market segments, market trends, and opportunities, and any further data you may need to thrive in the microbiome industry. This microbiome market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The microbiome market size has grown exponentially in recent years. It will grow from $0.68 billion in 2024 to $0.82 billion in 2025 at a compound annual growth rate (CAGR) of 20.1%. The growth in the historic period can be attributed to increased need for immunology, increasing collaborations, government initiatives, increased healthcare expenditure and growth in the number of healthcare facilities.
The microbiome market size is expected to see rapid growth in the next few years. It will grow to $1.43 billion in 2029 at a compound annual growth rate (CAGR) of 15.0%. The growth in the forecast period can be attributed to rise in healthcare expenditure, rising requirement for customized medicine, increasing funding, technological advances and rising prevalence of chronic diseases. Major trends in the forecast period include use of artificial intelligence, strategic collaborations and agreements, boost revenues and establish category leadership, increasing the number of pipeline studies to develop microbiome therapeutics to treat different diseases, consider investing in the development of oncology microbiome therapeutics and to improve productivity, efficiency and accuracy of the precision technologies.
The growing prevalence of inflammatory bowel disease (IBD) is a significant factor propelling the growth of the microbiome market. IBD encompasses a group of chronic inflammatory disorders that impact the digestive tract, particularly the gastrointestinal (GI) tract. This focus on IBD has highlighted the crucial role of the gut microbiome in the disease, resulting in a surge of research, diagnostics, and therapies centered on the microbiome, which is fueling the market's expansion. For example, in September 2022, the American Gastroenterological Association (AGA), a U.S.-based medical association for gastroenterologists, reported that 40% of Americans have disrupted their daily activities due to uncomfortable bowel symptoms. Additionally, 60-70 million Americans are affected by gastrointestinal diseases that significantly impair their quality of life. Thus, the rising prevalence of IBD is expected to drive the growth of the microbiome market.
Increasing healthcare expenditure is anticipated to further stimulate the growth of the microbiome market. Healthcare expenditure refers to the total funds allocated for healthcare services, goods, and activities within a particular healthcare system or economy over a specified timeframe. These expenditures are crucial for advancing the microbiome market. With rising investments in microbiome research and development and growing awareness of the microbiome's importance for human health, there is an increasing demand for microbiome-based therapies and products. For instance, in March 2022, the Centers for Medicare and Medicaid Services (CMS), a U.S. federal agency, projected that national health spending would rise by an average of 5.1% annually between 2021 and 2030, reaching approximately $6.8 trillion by 2030. Therefore, the escalation in healthcare expenditures is driving growth in the microbiome market.
Technological improvement is emerging as a significant trend in the microbiome market. Major companies in the microbiome sector are actively developing advanced technological solutions, such as Seed's introduction of the Probiotic and Prebiotic Daily Synbiotic for both females and males. Seed's Daily Synbiotic adopts a microbe-system strategy, providing strain-specific benefits beyond digestive health, including cardiac safety, dermatological health, immune control, reproductive health, gut barrier integrity, and oxidative stress.
Major companies in the microbiome market are prioritizing innovation, such as personalized health insights designed to empower individuals by providing tailored reports that highlight specific health issues. Personalized health insights entail customized, data-driven information and recommendations tailored to an individual's unique health profile. For instance, in September 2024, Redcliffe Labs, an India-based medical and diagnostic laboratory company, introduced Gut Microbiome and HealthEx tests aimed at improving preventive healthcare through personalized health insights. These two specialized health tests focus on promoting preventive healthcare. The gut microbiome test evaluates gut health and provides insights into immune function, metabolism, and mental well-being. Meanwhile, an advanced blood test analyzes DNA to identify potential health risks associated with lifestyle, diet, and genetics. Both tests offer personalized recommendations to help individuals manage their health effectively.
In December 2023, L'Oreal S.A., a France-based cosmetics company, acquired Lactobio for an undisclosed sum. This acquisition aims to enhance L'Oreal S.A.'s expertise in microbiome science, enriching its product offerings by integrating innovative probiotic-based solutions. Lactobio, a biotechnology research company based in Denmark, utilizes microbiome science to develop novel health interventions.
Major companies operating in the microbiome market include Seres Therapeutics, Enterome Bioscience, Ferring Pharmaceuticals, Vedanta BioSciences, Second Genome Inc., Microbiotica, Rebiotix, Inc, Locus Biosciences, Osel Inc., Xbiome Co., Ltd, Microba Life Sciences, Biome Australia, Shoreline Biome, Leucine Rich Bio Pvt Ltd, BugSpeaks, KINS Co., Ltd, Yeda Research and Development Co. Ltd, China National Pharmaceutical Group Corporation, Atlas Biomed, BiomX Ltd, ImmuneBiotech Medical Sweden AB, MetaboGen AB, ADM Biopolis, Viome, PharmaBiome, NCCR Microbiomes, MaaT Pharma, Eligo Bioscience, T3 Pharmaceuticals, MicroBiome Therapeutics LLC, OpenBiome, Microbiome Insights Inc., Lallemand Health Solutions, Mybiotics Pharma, DayTwo, Next Biosciences, ViThera Pharmaceuticals Inc., Inqaba Biotechnical Industries (Pty), SNIPR Biome, MyBiome
North America was the largest region in the microbiome market in 2024. The regions covered in the microbiome market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
The countries covered in the microbiome market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Canada, Spain
The microbiome market consists of sales of firmicutes, bacteroidetes, and actinobacteria. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Microbiome Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on microbiome market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for microbiome ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The microbiome market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.